Sanjay Popat

@DrSanjayPopat

Professor, Consultant Thoracic Oncologist, ; Chair ; ; views are my own. No DMs or specific medical advice given.

London, England
Vrijeme pridruživanja: rujan 2016.

Tweetovi

Blokirali ste korisnika/cu @DrSanjayPopat

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @DrSanjayPopat

  1. Prikvačeni tweet
    2. lis 2017.

    Brief tweet to note my apologies but I can’t respond to specific requests for medical advice or DMs

    Poništi
  2. proslijedio/la je Tweet
    prije 3 sata

    Treatment for both tumors guided by biology: for NSCLC high TMB & high PD1; for MM t(11;14). Excellent multi-disciplinary care and . CD38 a potential target in NSCLC? a fascinating n=1 case, strong support for venetoclax t11;14 MM

    Prikaži ovu nit
    Poništi
  3. proslijedio/la je Tweet
    prije 3 sata

    Patient was treated w/ pembrolizumab whilst on carfilzomib/daratumumab with excellent ongoing NSCLC PR. Subsequent MM relapse (whilst on pembro for NSCLC) treated with venetoclax due to t(11;14) with sustained ongoing VGPR (meanwhile CR). No significant AEs, no tx interruptions.

    Prikaži ovu nit
    Poništi
  4. proslijedio/la je Tweet
    prije 3 sata

    The challenge of managing two concurrent cancers - we present an interesting case of relapsed MM also diagnosed with advanced NSCLC.

    Prikaži ovu nit
    Poništi
  5. proslijedio/la je Tweet

    We are very pleased to have contributed to the publication of The Pan Cancer Analysis of Whole Genomes - PCAWG - project. You can view the collection of papers from here:

    Poništi
  6. proslijedio/la je Tweet
    prije 14 sati

    This paper has analyzed 2,658 whole-cancer genomes &matching normal tissues in 38 tumour types. On average, cancer genomes had 4–5 driver mutations ; however, in 5% of cases no drivers were identified: discoveries are yet to be made in such tumors

    Poništi
  7. proslijedio/la je Tweet
    prije 16 sati

    WOW‼️Largest pan-cancer whole genome analyses in - new biol. details & RNAseq import. Yet detailed clin & prosp. pts outcomes data are needed to fully understand the clinical importance of these findings in an unbiased fashion.

    Poništi
  8. proslijedio/la je Tweet

    Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition (Rodriguez-Martin et al.)

    Poništi
  9. 5. velj

    Lorlatinib is an important drug for relapsed ALK+ . Am hoping there will be constructive dialogue between NICE and Pfizer to allow an agreement on price.

    Poništi
  10. 31. sij

    Returning home from & reflecting on & inspired by all the amazing work we discussed in UK & globally, led and delivered by amazing colleagues & advocates. See you all again next year for !

    Poništi
  11. proslijedio/la je Tweet
    31. sij

    Great ways of delivering presented by using bundles all published on the website incl integration of physiology and optimisation bundle. Would be a major step forward if we could all implement this.

    Poništi
  12. 31. sij

    Nice thread on “Study adds to the evidence that reduces lung cancer mortality, a fact that should now be considered as confirmed”

    Poništi
  13. 31. sij

    . presents rapid diagnostic pathway with bundled investigations continuing on CT findings: proven to reduce time to treatment. Investigation bundles available at

    Poništi
  14. proslijedio/la je Tweet
    30. sij
    Odgovor korisnicima i sljedećem broju korisnika:

    We would love to see more Radiologists at the 2020 UK Oncology Forum! We hope that some of you can join us 11&12 June, Birmingham FREE, CME accredited & post ASCO highlights Dr Alison Tree heads up a leading team UK & European expert RT speakers!

    Poništi
  15. 30. sij

    . discusses optimal RT. Highlights PACIFIC4 & SWOG/NRG S1914 Ix IO+SBRT. For St 3 experience matters in 0617. NRG1106 PET-adapted RT ongoing. Need data on 3DRT vs protons: perhaps pneumonitis risk differences? NRG1308 may answer. FlashRT to be explored

    Poništi
  16. 30. sij

    . discusses IO for stage 3. PACIFIC has changed paradigm. Control arm comparable to 0617 & PROClAIM. EU expert disagreement with EMA on PDL1negs. ctDNA for MRD encouraging data. Biggest challenge is UK st3 pts getting curative Tx. Must improve!!

    Poništi
  17. 30. sij

    . discusses surgery for N2 disease. Most surgery in UK is primary and not post induction chemo-RT. Important to subclassify N2 for routine datasets. How to inter grants IO? Need data on LungART and IO trials

    Poništi
  18. 30. sij

    Kevin Franks discusses indications & outcomes for SBRT. Awaiting STABLE-MATES & VALOR. Epic efforts for these trials. Pt preferences are crucial. <30% consented to SABRTooth

    Poništi
  19. 30. sij

    . highlights VIOLET outcomes with reduced pain & stay. Completed early. Same node numbers & no sign nodal upstaging. 26% reduction in AEs. VATS is now standard care

    Poništi
  20. proslijedio/la je Tweet
    30. sij

    Please visit the stand next to the posters to say hello to the team and pick up a copy of our new audit reports

    Poništi
  21. proslijedio/la je Tweet
    30. sij

    Come and join us at our stand at and pick up advance copies of our new hot off the press reports being officially launched tomorrow.

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·